Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 13

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 13
---
 trading market                                                                                                                      
 for our Common Stock may never develop or be sustained.                                                                                       |
| ● | Unstable market and economic                                                                                                                  
 conditions may have serious adverse consequences on our business, financial condition and stock price.                                        |
| ● | If the Selling Stockholders                                                                                                                   
 sell into the market all Shares registered in the Resale Offering, it could cause the market price of our Common Stock to drop significantly, 
 even if our business grows                                                                                                                    |
| ● | Negative research about                                                                                                                       
 our business published by analysts or journalists could cause our stock price to decline. A lack of regularly published research              
 about our business could cause trading volume or our stock price to decline.                                                                  |

<div align='center'>7

Risks Related to Our Business and Financial Condition</div>

We have a History of Losses and May Never Achieve Profitability.

We are a pre-clinical stage biopharmaceutical company with no commercial products. We have operated at a loss since inception, and we anticipate that we will incur operating losses and negative cash flow in the foreseeable future. We have not yet commercialized any products and cannot be sure that we will ever be able to do so, or that we may ever achieve profitability. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research, development and clinical efforts. If these activities are successful and if we receive positive results from the clinical trials and subsequently from the FDA to market our novel therapies, then even more funding will be required to market those. The outcome of these matters cannot be predicted at this time. We expect to expand our clinical trials significantly, which will result in increasing losses, and may continue to incur substantial losses before we begin to generate revenues from the development and marketing of our technology. There can be no assurance that we successfully raise additional funds and that we will achieve positive cash flow. If we are unable to raise additional funds under terms acceptable to us and in the interests of our stockholders, then we will have to scale back or discontinuing one or more of our aspects of operations, including stopping or delaying planned clinical trials.

We will need substantial additional funding to realize our business plan, due to a number of factors, some of which are beyond our control. We may not be able to raise capital when needed, if at all, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts and could cause our business to fail.

Our operations have consumed substantial amounts of cash since inception. We